RecruitingEarly Phase 1

Growth Hormone for the Treatment of Gastroparesis

United States10 participantsStarted 2024-10-22

Plain-language summary

The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Symptoms \> 6 months that have not responded satisfactorily to standard treatment. * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21 Exclusion Criteria: * Known history of GH deficiency, hypothalamic or pituitary disease * Diabetes * Prior use of GH therapy * Age-adjusted low serum IGF1 * Women on oral estrogen therapy6 * Pregnancy or nursing * History of malignant solid tumors * Obesity (BMI \> 30)History of coronary and thromboembolic diseases. * History of sarcoidosis * History of pituitary surgery * History of thyroid nodules. * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. * Failure to give informed consent.

What they're measuring

Gastroparesis Cardinal Symptom Index (GCSI)

Timeframe: Baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks

Trial details

NCT IDNCT06803589

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10

Contact for this trial

Guillermo GI Program Coordinator, Research

480-301-4679 barahona.guillermo@mayo.edu

View on ClinicalTrials.gov More Gastroparesis trials